Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.54 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.54 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.54 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3984508 | 1.00 | KLK5 (0.65) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL5171370 | 1.00 | KLK5 (0.65) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL495758 | 1.00 | KLK5 (0.65) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL1481008 | 1.00 | KLK5 (0.65) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL638912 | 1.00 | KLK5 (0.65) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL640670 | 1.00 | KLK5 (0.65) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL13537629 | 0.90 | KLK5 (0.55) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL6158017 | 0.90 | KLK5 (0.55) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL6158094 | 0.90 | KLK5 (0.55) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL6158009 | 0.90 | KLK5 (0.55) | KLK5ATMPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111662889-B | Ketoreductase mutant for producing darunavir intermediate | 南京朗恩生物科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-111705043-B | Ketoreductase mutant with improved catalytic activity and application thereof | 南京朗恩生物科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-111690696-B | Method for preparing darunavir intermediate through biocatalysis | 南京朗恩生物科技有限公司 | 2021-12-31 | — | — | CN | claimed |
| EP-3409765-B1 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | CODEXIS INC (US) | 2021-08-04 | — | — | EP | claimed |
| CN-111705043-A | Ketoreductase mutant with improved catalytic activity and application thereof | 南京朗恩生物科技有限公司 | 2020-09-25 | — | — | CN | claimed |
| CN-111690696-A | Method for preparing darunavir intermediate through biocatalysis | 南京朗恩生物科技有限公司 | 2020-09-22 | — | — | CN | claimed |
| CN-111662889-A | Ketoreductase mutant for producing darunavir intermediate | 南京朗恩生物科技有限公司 | 2020-09-15 | — | — | CN | claimed |
| EP-2446025-B1 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | CODEXIS INC (US) | 2018-08-08 | — | — | EP | claimed |
| CN-105152978-B | A kind of preparation method of the butanol of 3 tert-butoxycarbonylamino of (2R, 3S) 1 chlorine, 4 phenyl 2 | 上海应用技术学院 | 2017-08-25 | — | — | CN | claimed |
| CN-109942514-B | Method for preparing azalazavir sulfate intermediate | 淮海工学院 | 2022-09-09 | — | — | CN | disclosed |
| CN-109943542-B | Alcohol dehydrogenase for producing atazanavir intermediate | 南京诺云生物科技有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-111662889-B | Ketoreductase mutant for producing darunavir intermediate | 南京朗恩生物科技有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-111705043-B | Ketoreductase mutant with improved catalytic activity and application thereof | 南京朗恩生物科技有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-111662889-B | Ketoreductase mutant for producing darunavir intermediate | 南京朗恩生物科技有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20020035288-A1 | Process for producing alpha-aminoketones | AJINOMOTO CO., INC. (JP) | 2002-03-21 | — | — | US | disclosed |
| US-20020013499-A1 | Process for producing alpha-aminoketones | AJINOMOTO CO., INC. (JP) | 2002-01-31 | — | — | US | disclosed |
| EP-1148046-A1 | PROCESS FOR THE PREPARATION OF ALPHA-AMINOKETONES | Ajinomoto Co., Inc. (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6255522-B1 | USING AS REDUCING AGENT A REACTION PRODUCT OF ORGANOALUMINUM COMPOUND, SULFONATE AND ALCOHOL | KANEKA CORPORATION (JP) | 2001-07-03 | — | — | US | disclosed |
| EP-1081133-A1 | Method for producing N-carbamate-protected beta-aminoepoxide and beta-aminoalcohol | Ajinomoto Co., Inc. (JP) | 2001-03-07 | — | — | EP | disclosed |
| EP-0969000-A1 | PROCESS FOR REDUCING $G(a)-AMINO KETONES | KANEKA CORPORATION (JP) | 2000-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035288-A1 | Process for producing alpha-aminoketones | AAAS, BCKDK, KHK | KLK5 123/4885ATM 1421/4885PSEN1 3086/4885 |
| US-20020013499-A1 | Process for producing alpha-aminoketones | AADAT, BCAT2, BCKDK | KLK5 614/4885ATM 325/4885PSEN1 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.